Orchestra BioMed (OBIO) Director Awarded 15,000 RSUs, Vest in One Year

Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) director Pamela Ann Connealy was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to one share of common stock and the reported acquisition is recorded at a $0 price.

The RSUs are scheduled to vest on the one‑year anniversary of the grant date, subject to the reporting persons continuous service through that date. Following the award, Ms. Connealy beneficially owns 48,711 shares of common stock, held directly.

The filing lists Ms. Connealys relationship to the issuer as a director. No derivative securities or dispositions are reported in this Form 4.

Positive

• 15,000 RSUs awarded, representing potential alignment with shareholders through equity compensation
• Time‑based vesting (one year) incentivizes retention and continued service

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received 15,000 RSUs vested after one year, increasing direct holdings to 48,711 shares; transaction is a routine equity award.

The grant of 15,000 RSUs at a reported price of $0 is a straightforward equity compensation event for a director. It increases direct beneficial ownership to 48,711 shares and carries a one‑year service‑based vesting condition. From a liquidity or valuation perspective, the Form 4 does not disclose any sale, purchase for cash, or derivative transactions, so the market impact is likely limited absent further disclosures.

Corporate Governance Expert

TL;DR: This is a standard retention/incentive grant to a director with time‑based vesting; governance implications are routine and non‑material alone.

As reported, the award aligns a directors interests with shareholders through equity compensation that vests after continued service. The Form 4 shows direct ownership and no complex indirect holdings or derivative instruments. There are no red flags in the disclosure itself; it documents a common governance practice of using RSUs for director compensation and retention.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Connealy Pamela Ann

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW YORK PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	08/07/2025		A		15,000(1)	A	$0	48,711	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.

	/s/ Andrew Taylor, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OBIO director Pamela Ann Connealy receive?

She was awarded 15,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock.

When do the RSUs vest for Pamela Ann Connealy?

The RSUs vest on the one‑year anniversary of the grant date, subject to continuous service through that date.

How many OBIO shares does Pamela Connealy beneficially own after the grant?

Following the award, she beneficially owns 48,711 shares of common stock, held directly.

What price was reported for the RSU acquisition?

The reported acquisition price for the RSUs is $0.

Was any derivative security reported in the Form 4 for OBIO?

No derivative securities were reported; Table II shows no entries.